These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 31118055

  • 1. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
    Li M, Yang J, Zhang L, Tu S, Zhou X, Tan Z, Zhou W, He Y, Li Y.
    J Exp Clin Cancer Res; 2019 May 22; 38(1):211. PubMed ID: 31118055
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct 22; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 3. FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.
    Wen Q, Jiao X, Kuang F, Hou B, Zhu Y, Guo W, Sun G, Ba Y, Yu D, Wang D, Zhang F, Qiao HC, Wang S, Tang S, Qiao H.
    EBioMedicine; 2019 Feb 22; 40():198-209. PubMed ID: 30738830
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z, Zhang SL, Hu X, Tam KY.
    Eur J Pharmacol; 2018 Nov 05; 838():41-52. PubMed ID: 30213498
    [Abstract] [Full Text] [Related]

  • 5. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Nov 05; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 6. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.
    Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.
    Clin Cancer Res; 2018 Dec 15; 24(24):6523-6535. PubMed ID: 30194074
    [Abstract] [Full Text] [Related]

  • 7. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    Lung Cancer; 2014 Aug 15; 85(2):152-60. PubMed ID: 24954871
    [Abstract] [Full Text] [Related]

  • 8. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W, Chen Y, Zhu KY, Deng H, Wu T, Wang J.
    Biol Pharm Bull; 2017 Aug 01; 40(8):1306-1313. PubMed ID: 28515374
    [Abstract] [Full Text] [Related]

  • 9. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
    Wang L, Dong X, Ren Y, Luo J, Liu P, Su D, Yang X.
    Cell Death Dis; 2018 Jan 26; 9(2):129. PubMed ID: 29374157
    [Abstract] [Full Text] [Related]

  • 10. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
    Xu L, Meng X, Xu N, Fu W, Tan H, Zhang L, Zhou Q, Qian J, Tu S, Li X, Lao Y, Xu H.
    Cell Death Dis; 2018 Feb 15; 9(3):262. PubMed ID: 29449529
    [Abstract] [Full Text] [Related]

  • 11. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation.
    Wang G, Zhao J, Zhang M, Wang Q, Chen B, Hou Y, Lu K.
    Int J Nanomedicine; 2019 Feb 15; 14():4503-4515. PubMed ID: 31417255
    [Abstract] [Full Text] [Related]

  • 12. A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity.
    Xie X, Zhou W, Hu Y, Chen Y, Zhang H, Li Y.
    Cell Death Dis; 2018 Mar 07; 9(3):379. PubMed ID: 29515106
    [Abstract] [Full Text] [Related]

  • 13. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 14. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 15. Reversal of EGFR inhibitors' resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer.
    He F, Wang Y, Cai W, Li M, Dong L.
    Biosci Rep; 2019 Aug 30; 39(8):. PubMed ID: 31316001
    [Abstract] [Full Text] [Related]

  • 16. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 30; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 17. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P, Stewart E, Pham NA, Mascaux C, Panchal D, Li M, Kim L, Sakashita S, Wang D, Sykes J, Friess T, Shepherd FA, Liu G, Tsao MS.
    Clin Lung Cancer; 2016 Sep 30; 17(5):375-383.e2. PubMed ID: 26926157
    [Abstract] [Full Text] [Related]

  • 18. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
    Clin Cancer Res; 2011 Apr 15; 17(8):2260-9. PubMed ID: 21220474
    [Abstract] [Full Text] [Related]

  • 19. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M, Codony-Servat C, Codony-Servat J, Lligé D, Chaib I, Sun X, Miao J, Sun R, Cai X, Verlicchi A, Okada M, Molina-Vila MA, Karachaliou N, Cao P, Rosell R.
    Cell Commun Signal; 2019 Oct 28; 17(1):137. PubMed ID: 31660987
    [Abstract] [Full Text] [Related]

  • 20. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.
    Chen Y, Xie X, Wu A, Wang L, Hu Y, Zhang H, Li Y.
    J Exp Clin Cancer Res; 2018 Jan 22; 37(1):12. PubMed ID: 29357910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.